Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease

CONTEXT: Inhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin receptor antibodies (TSH-R-Ab) that drive pathology in thyroid eye disease (TED). OBJECTIVE: We report the first clinical studies of an FcRn inhibitor, batoclimab, in TED. DESIGN: Proof-of-conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahaly, George J, Dolman, Peter J, Wolf, Jan, Giers, Bert C, Elflein, Heike M, Jain, Amy P, Srinivasan, Ashok, Hadjiiski, Lubomir, Jordan, David, Bradley, Elizabeth A, Stan, Marius N, Eckstein, Anja, Pitz, Susanne, Vorländer, Christian, Wester, Sara T, Nguyen, John, Tucker, Nancy, Sales-Sanz, Marco, Feldon, Steven E, Nelson, Christine C, Hardy, Isabelle, Abia-Serrano, Maravillas, Tedeschi, Philip, Janes, Jonathan M, Xu, Jing, Vue, Peter, Macias, William L, Douglas, Raymond S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655547/
https://www.ncbi.nlm.nih.gov/pubmed/37390454
http://dx.doi.org/10.1210/clinem/dgad381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655547/
https://www.ncbi.nlm.nih.gov/pubmed/37390454
http://dx.doi.org/10.1210/clinem/dgad381

Ejemplares similares